Neuroprotective Effect Of Riluzole In Rat Model Of Subarachnoid Hemorrhage

Tao Wang,Xin-Na Zhang,Lin Wang,Ying-Chun Liang,Lei Zhang,Da-Peng Zhao,Yun-Lin Liu
2018-01-01
Abstract:Riluzole, an anti-glutamate drug and sodium channel blocker with neuroprotective roles, which has been approved by US Food and Drug Administration (FDA) for amyotrophic lateral sclerosis. The purpose of this study was to explore whether Riluzole provides neuroprotection in early brain injury (EBI) after subarachnoid hemorrhage (SAH). Intraperitoneal injection of Riluzole (6 mg/kg) significantly improved neurological deficit at 24, 48 and 72 h. Riluzole alleviated the blood brain barrier (BBB) permeability of cortex and brain edema, also reduced the glutamate concentration of cerebrospinal fluid, increased the GLT-1 expression of cortex, increased GSH content and attenuated MDA content and neuronal apoptosis of cortex at 72 h after SAH. These results suggested that Riluzole treatment may ameliorate early brain injury in experimental SAH model.
What problem does this paper attempt to address?